Grifols will float its biopharma business in the US

Grifols will float part of its business on the stock exchange biopharma In the US, the board of the company specializing in blood products has approved it at the proposal of the strategy committee. The goal is to strengthen self-sufficiency in plasma, one of its raw materials, as is the case in Egypt and Canada.